Avelumab with axitinib for untreated advanced renal cell carcinoma – guidance (TA645)

Avelumab with axitinib is recommended for use within the Cancer Drugs Fund as an option for untreated advanced renal cell carcinoma in adults. It is recommended only if the conditions in the managed access agreement for avelumab with axitinib are followed.

National Institute for Health and Care Excellence